Disease · MONDO_0006525
allergic contact dermatitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. allergic contact dermatitis. Diseases, record MONDO_0006525. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006525
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ANAKINRA | CHEMBL1201570 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SULFADIAZINE, SILVER | CHEMBL1382627 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| APREMILAST | CHEMBL514800 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYALURONIDASE (HUMAN RECOMBINANT) | CHEMBL1201718 | Enzyme | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NI-0801 | CHEMBL2109379 | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CXCL10 | C-X-C motif chemokine 10 | 1 | C-X-C motif chemokine 10 inhibitor | Phase 1 | https://conductscience.org/library/genes/3627 | Drugs and targets |
| IL17A | Interleukin-17A | 1 | Interleukin 17A inhibitor | Phase 3 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| PDE4A | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5144 | Drugs and targets |
Trials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00928447 | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis | Phase 2 | 22 | 2021-12-17 | Dermatitis, Allergic Contact | HYALURONIDASE (HUMAN RECOMBINANT) | Its record names the disease | ClinicalTrials.gov |
| NCT05498467 | The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis | Phase 3 | 20 | 2025-05-20 | Allergic Contact Dermatitis | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
| NCT00931242 | Study of Apremilast in Atopic or Contact Dermatitis | Phase 2 | 10 | 2010-12-20 | Atopic Dermatitis, Allergic Contact Dermatitis | APREMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT02109718 | A Trial Comparing the Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine | Phase 3 | 50 | Superficial Partial Thickness Burns | SULFADIAZINE, SILVER | Its record names the disease | ClinicalTrials.gov | |
| NCT01244607 | NI-0801 in Allergic Contact Dermatitis | Phase 1 | 22 | Allergic Contact Dermatitis | NI-0801 | Its record names the disease | ClinicalTrials.gov | |
| NCT02778711 | Anti-IL-17 a New Treatment for Contact Dermatititis | Phase 3 | 20 | Allergic Contact Dermatitits | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anakinra vs Placebo: deaths from any cause | 0 of 12 | 0 of 8 | 20 | NCT05498467 | Trial comparisons |
| Anakinra vs Placebo: serious adverse events | 0 of 12 | 0 of 8 | 20 | NCT05498467 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 25172229 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006525
GET https://conductscience.org/api/diseases/v1/MONDO_0006525/drugs